Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Trial details
- Registry ID
- NCT07428499
- Drugs studied
- ADX-324 Dose Level 1, ADX-324 Dose Level 2
TrialRedline tracks 5 clinical trials sponsored by ADARx Pharmaceuticals, Inc.: 2 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)NCT07428499 | ADX-324 Dose Level 1, ADX-324 Dose Level 2 | Recruiting | 2030-06-30Estimated |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAENCT06960213 | ADX-324 | Recruiting | 2027-11-30Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseNCT06989359 | ADX-038 Dose Level 1, ADX-038 Dose Level 2, ADX-038 Dose Level 3 | Recruiting | 2030-04-30Estimated |
| Phase 2 Study of ADX-038 in Participants With Geographic AtrophyNCT06990269 | ADX-038 | Recruiting | 2030-02-28Estimated |
| Chinese Adults With Kidney DiseaseNCT07522099 | ADX-038, Telitacicept | Recruiting | 2028-07-10Estimated |
Names as written in the registry records.
NCT06989359 · ADARx Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - 36 months. After: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - From Day 1 through Month 24.
Before: 45 participants (planned). After: 85 participants (planned).
Before: 31 Dec 2028. After: 30 Apr 2030.
NCT06960213 · ADARx Pharmaceuticals, Inc.
Before: 30 Jun 2027. After: 30 Nov 2027.
NCT07428499 · ADARx Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT06990269 · ADARx Pharmaceuticals, Inc.
Before: 30 Sep 2027. After: 28 Feb 2030.
NCT06989359 · ADARx Pharmaceuticals, Inc.
Before: Jul 2027. After: 31 Dec 2028.
NCT07522099 · ADARx Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT06960213 · ADARx Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy of ADX-324 in preventing investigator-confirmed HAE attacks. After: Measure: Efficacy of ADX-324 in preventing HAE attacks.
Before: 31 Dec 2026. After: 30 Jun 2027.
NCT06990269 · ADARx Pharmaceuticals, Inc.
Before: Sep 2027. After: 30 Sep 2027.
Before: Not yet recruiting. After: Recruiting.
NCT06989359 · ADARx Pharmaceuticals, Inc.
Before: 30 participants (planned). After: 45 participants (planned).
Before: Not yet recruiting. After: Recruiting.